Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: January 17, 2025
Subject: Announcement of headline results from the STEP UP Phase 3b clinical trial investigating semaglutide 7.2 mg for obesity treatment.
Key Financial Metrics
This filing is a clinical trial update and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The filing details the results of the STEP UP trial, a 72-week efficacy and safety study involving 1,407 randomized adults with obesity. Key findings include:
- Primary Endpoint: Semaglutide 7.2 mg demonstrated statistically significant and superior weight loss versus placebo.
- Weight Loss (Treatment Product Estimand):
- Semaglutide 7.2 mg: 20.7% reduction (baseline 113 kg).
- Semaglutide 2.4 mg: 17.5% reduction.
- Placebo: 2.4% reduction.
- Weight Loss (Treatment Policy Estimand):
- Semaglutide 7.2 mg: 18.7% reduction.
- Semaglutide 2.4 mg: 15.6% reduction.
- Placebo: 3.9% reduction.
- High-Response Rate: 33.2% of patients on semaglutide 7.2 mg achieved weight loss of 25% or more, compared to 16.7% on 2.4 mg and 0.0% on placebo.
- Safety Profile: Semaglutide 7.2 mg appeared safe and well-tolerated. Most common adverse events were gastrointestinal, mild to moderate, and diminished over time.
Guidance, Outlook, and Management Commentary
Management Commentary: Martin Holst Lange, Executive Vice President for Development, stated the results strengthen the clinical profile of semaglutide for obesity, noting the safety profile is comparable to the approved 2.4 mg dose (Wegovy®). The results complement established cardiovascular risk reduction benefits seen in the SELECT trial.
Outlook and Future Events:
- STEP UP T2D: Results from the second Phase 3 trial in adults with type 2 diabetes and obesity are expected within the next few months.
- Scientific Presentation: Detailed results from the STEP UP trial are expected to be presented at a scientific conference in 2025.
Investor Verification Checklist
- Verify the regulatory status and potential approval timeline for semaglutide 7.2 mg in key markets (US, EU).
- Monitor the upcoming presentation of detailed STEP UP data at the 2025 scientific conference.
- Track the release of STEP UP T2D results expected in the coming months.
- Assess the potential impact of the 7.2 mg dose on the competitive landscape of GLP-1 receptor agonists.
- Review subsequent financial reports for revenue impact from potential new indications or dose approvals.